- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Journey Medical signals continued ASP gains in 2H 2026 as Emrosi reaches $8.1M and 38% high-quality coverage | 19 | Seeking Alpha | ||
| 12.08. | Journey Medical steigert Umsatz im zweiten Quartal 2026 und erreicht positives EBITDA | 1 | Investing.com Deutsch | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.08. | Journey Medical übertrifft Prognosen für Q2 2026 - Aktie legt zu | 1 | Investing.com Deutsch | ||
| 12.08. | Journey Medical Non-GAAP EPS of $0.10, revenue of $18.5M beats by $0.13M | 2 | Seeking Alpha | ||
| 12.08. | Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | 156 | GlobeNewswire (Europe) | Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi revenues were $8.1 million for the second quarter of 2026 Strong revenue... ► Artikel lesen | |
| 05.08. | Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026 | 1 | GlobeNewswire (USA) | ||
| 14.05. | Journey Medical signals positive EBITDA for remainder of 2026 as it plans to add up to 5 sales professionals | 3 | Seeking Alpha | ||
| 13.05. | Journey Medical: Starker Gewinn pro Aktie, aber Umsatz enttäuscht | 9 | Investing.com Deutsch | ||
| 13.05. | Transcript: Journey Medical Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 13.05. | Journey Medical: EPS übertrifft Schätzungen um 0,05 $ - Umsatz schlechter als erwartet | 1 | Investing.com Deutsch | ||
| 13.05. | Journey Medical Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 319 | GlobeNewswire (Europe) | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen | |
| 06.05. | Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026 | 2 | GlobeNewswire (USA) | ||
| 21.04. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi | 2 | GlobeNewswire (USA) | ||
| 26.03. | Journey Medical stock rating reiterated at Buy by H.C. Wainwright | 4 | Investing.com | ||
| 26.03. | Journey Medical targets expanded Emrosi coverage and EBITDA growth through 2026 amid robust prescription demand | 2 | Seeking Alpha | ||
| 25.03. | Journey Medical Non-GAAP EPS of $0.10, revenue of $61.6M misses by $3.05M | 1 | Seeking Alpha | ||
| 25.03. | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | 414 | GlobeNewswire (Europe) | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 24,110 | -0,72 % | Nur ganze 16 bieten im S&P 500 mehr Dividende als die 10J-Staatsanleihen? Platz 1 VICI Properties, Platz 2 Pfizer... | Nur 16 Unternehmen im S&P 500 bieten noch eine Dividende, die höher liegt als die aktuelle Rendite der 10-jähringen Treasuries um 4,7 %. Das ist die kleinste Anzahl seit 2007. Unten im Anhang finden... ► Artikel lesen | |
| GILEAD SCIENCES | 127,34 | +0,20 % | AWSX der Telegram-Trader.de: Gilead:Trodelvy bekommt in Europa deutlich mehr Gewicht-Wo liegen die Kursziele? | ||
| ELI LILLY | 1.018,40 | -0,22 % | Eli Lilly wird zum Gefangenen des eigenen Erfolgs | 23 Mrd. US-Dollar Quartalsumsatz wären für viele Pharmakonzerne bereits die ganze Geschichte. Bei Eli Lilly sind sie inzwischen nur der Ausgangspunkt. Der Konzern wächst mit einem Tempo, das im klassischen... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 471,25 | +0,33 % | Vertex Pharmaceuticals-Aktie: Noch mehr Dominanz voraus | Der US-Biopharmakonzern Vertex Pharmaceuticals behauptet seine dominante Stellung bei Medikamenten gegen Mukoviszidose - und erhält dabei unerwartete Schützenhilfe ausgerechnet von einem gescheiterten... ► Artikel lesen | |
| INNOCAN PHARMA | 1,310 | -2,96 % | InnoCan Pharma im Krisenmodus: Trotz 29,7% Umsatzplus neues Allzeittief | ||
| EYEPOINT | 3,920 | -8,41 % | XFRA PV3B: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 242,00 | -2,42 % | Ligand Pharmaceuticals: Royalty-Modell gewinnt an Dynamik | ||
| JAZZ PHARMACEUTICALS | 211,90 | -0,94 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases | DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable... ► Artikel lesen | |
| UNITED THERAPEUTICS | 441,70 | -0,36 % | United Therapeutics Says FDA Accepts NDA For Ralinepag To Treat Pulmonary Arterial Hypertension | WASHINGTON (dpa-AFX) - United Therapeutics Corp. (UTHR), a public benefit corporation, announced Monday that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application... ► Artikel lesen | |
| OPKO HEALTH | 1,270 | -2,31 % | OPKO Health, Inc.: OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests | MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business of KKR (HCRx), through... ► Artikel lesen | |
| JAGUAR HEALTH | 0,931 | +1,29 % | Jaguar Health, Inc.: Commercial Launch Initiated for Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs | Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI... ► Artikel lesen | |
| ROYALTY PHARMA | 52,84 | -0,34 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 68,36 | +0,34 % | BridgeBio Pharma, Inc.: BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM | - The ASCEND-ATTR study builds on the Phase 3 ATTRibute-CM CMR substudy results previously shared here, which indicated treatment with acoramidis may improve cardiac structure and function with evidence... ► Artikel lesen | |
| TG THERAPEUTICS | 47,300 | +0,21 % | TGTX Stock Alert: What to Know as Takeover Rumors Swirl Around TG Therapeutics |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,025 (-0,33 %) liegt der Kurs bei 7,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.